KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Receivables (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Change in Receivables for 15 consecutive years, with $16.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 592.92% to $16.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.3 million, a 1173.34% increase, with the full-year FY2025 number at $22.3 million, up 1173.34% from a year prior.
  • Change in Receivables was $16.4 million for Q4 2025 at Supernus Pharmaceuticals, up from $7.1 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $16.4 million in Q4 2025 to a low of -$22.0 million in Q1 2023.
  • A 5-year average of $698000.0 and a median of $2.9 million in 2021 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: tumbled 476.36% in 2023, then skyrocketed 592.92% in 2025.
  • Supernus Pharmaceuticals' Change in Receivables stood at $3.5 million in 2021, then tumbled by 59.6% to $1.4 million in 2022, then skyrocketed by 69.74% to $2.4 million in 2023, then crashed by 239.37% to -$3.3 million in 2024, then surged by 592.92% to $16.4 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Change in Receivables are $16.4 million (Q4 2025), $7.1 million (Q3 2025), and -$4.8 million (Q2 2025).